This paper is in the following e-collection/theme issue:

Digital Health, Telehealth and e-Innovation in Clinical Settings (560) Web-based and Mobile Health Interventions (4029) Prevention and Health Promotion (1369) Obesity and Nutrition as Public Health Problem (399)

Published on in Vol 14 (2025)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/63079, first published .
Glucagon-Like Peptide-1 Receptor Agonists Combined With Personalized Digital Health Care for the Treatment of Metabolic Syndrome in Adults With Obesity: Retrospective Observational Study

Glucagon-Like Peptide-1 Receptor Agonists Combined With Personalized Digital Health Care for the Treatment of Metabolic Syndrome in Adults With Obesity: Retrospective Observational Study

Glucagon-Like Peptide-1 Receptor Agonists Combined With Personalized Digital Health Care for the Treatment of Metabolic Syndrome in Adults With Obesity: Retrospective Observational Study

Authors of this article:

Hala Zakaria1 Author Orcid Image ;   Hadoun Jabri1 Author Orcid Image ;   Sheikha Alshehhi1 Author Orcid Image ;   Milena Caccelli1 Author Orcid Image ;   Joelle Debs1 Author Orcid Image ;   Yousef Said1 Author Orcid Image ;   Joudy Kattan1 Author Orcid Image ;   Noah Almarzooqi1 Author Orcid Image ;   Ali Hashemi1 Author Orcid Image ;   Ihsan Almarzooqi1 Author Orcid Image
Article Authors Cited by (3) Tweetations (3) Metrics

Journals

  1. Hong I, Hidalgo Ramos R, Dufner Krieger S, Secades D, Ortiz M, Moya Porras L, Piedra Pacheco A, Esquivel J. Effects of Tirzepatide on Low-Density Lipoprotein Cholesterol Levels in Adults: A Systematic Review. Cureus 2025 View
  2. Zakaria H, Paul G, Ali J, Takim K, Celso K, Almarzooqi A, Hashemi A, Almarzooqi I. Effectiveness of Tirzepatide and Semaglutide Within a Hybrid Care Model with Exploratory Dose–Response Analyses: A Real-World Evidence Study. Diabetes Technology and Obesity Medicine 2025;1(1):516 View
  3. Farley B, Radetich E, DAlessandro J, Bulaj G. Metformin-Enhanced Digital Therapeutics for the Affordable Primary Prevention of Diabetes and Cardiovascular Diseases: Advancing Low-Cost Solutions for Lifestyle-Related Chronic Disorders. Healthcare 2025;13(24):3220 View